Clinical Trial Update: Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial evaluating ablative bridging irradiation before CD19 CAR-T therapy in high-risk relapsed/refractory large B-cell lymphoma is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19 CAR-T (CD19-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING